Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.59 |
| ▸ | PLIN1 | O60240 | 2/20 | 0.59 |
| ▸ | RECQL | P46063 | 2/20 | 0.59 |
| ▸ | PLIN5 | Q00G26 | 2/20 | 0.59 |
| ▸ | ABHD5 | Q8WTS1 | 2/20 | 0.59 |
| ▸ | TNKS | O95271 | 1/20 | 0.59 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412144 | 1.00 | LMNA (0.59) | LMNAALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL5280005 | 0.87 | RAB9A (0.48) | LMNAALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL1372517 | 0.85 | HDAC3 (0.56) | LMNAALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL1372519 | 0.85 | HDAC3 (0.56) | LMNAALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL4780407 | 0.85 | HDAC3 (0.56) | LMNAALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL4780413 | 0.85 | HDAC3 (0.56) | LMNAALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL27628008 | 0.82 | HSD11B1 (0.64) | LMNAALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL7625602 | 0.82 | TYR (0.61) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL7625595 | 0.82 | TYR (0.61) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL31670724 | 0.81 | LMNA (0.52) | LMNAALDH1A1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103896958-B | Oridonin and ent-6,7-open loop dammara ene-type derivative purposes in terms of preparing antituberculotic thereof | 中国药科大学 | 2016-08-24 | — | — | CN | claimed |
| CN-103896958-A | Oridonin and use of ent-6,7-open-loop kaurene type derivative thereof in preparing antituberculosis medicaments | UNIV CHINA PHARMA | 2014-07-02 | — | — | CN | claimed |
| CN-102295649-A | Oridonin with antitumor resistance activity, 6,7-open ring oridonin fluorine-containing derivative, preparation method and application | — | 2011-12-28 | — | — | CN | claimed |
| US-8012975-B2 | These compounds lack a 1,4-bridging group as found in the ecteinascidins; and, have at the C-1 position a substituent selected from an amino or hydroxy group, optionally protected or derivatized; anticarcinogenic agents | PHARMA MAR, S.A. (ES) | 2011-09-06 | — | — | US | claimed |
| US-7410969-B2 | Antitumoral analogs of ET-743 | PHARMA MAR, S.A. (ES) | 2008-08-12 | — | — | US | claimed |
| US-20080051407-A1 | These compounds lack a 1,4-bridging group as found in the ecteinascidins; and, have at the C-1 position a substituent selected from an amino or hydroxy group, optionally protected or derivatized; anticarcinogenic agents | PHARMA MAR, S.A., A MADRID SPAIN CORPORATION | 2008-02-28 | — | — | US | claimed |
| EP-1496060-B1 | Antitumoral analogs of ET-743 | PHARMA MAR SA (ES) | 2007-08-01 | — | — | EP | claimed |
| US-7247629-B2 | Antitumoral analogs of et-743 | PHARMA MAR, S.A. | 2007-07-24 | — | — | US | claimed |
| WO-2007000329-A2 | EPOXIDATION OF ALPHA, BETA-UNSATURATED KETONES | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-04 | — | — | WO | claimed |
| US-20060019960-A1 | Antitumoral analogs of ET-743 | PHARMA MAR, S.A. (ES) | 2006-01-26 | — | — | US | claimed |
| CN-1211386-C | Antitumoral analogue of Et-743 | PHARMA MAR SA (ES) | 2005-07-20 | — | — | CN | claimed |
| EP-1289999-B1 | ANTITUMORAL ANALOGS OF ET-743 | PHARMA MAR SA (ES) | 2004-11-17 | — | — | EP | claimed |
| CN-1441805-A | Antitumoral analogue of Et-743 | PHARMA MAR SA (ES) | 2003-09-10 | — | — | CN | claimed |
| US-11945824-B2 | Heterocyclic compounds as anti-viral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| EP-1083171-A1 | PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND APPLICATION AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2001-03-14 | — | — | EP | disclosed |
| EP-0795547-B1 | (Aminoalkyl- and acylaminoalkyl-oxy)benzyloxyquinolines, process for their preparation and use as Bradykinin receptor antagonists | HOECHST AG (DE) | 2000-05-10 | — | — | EP | disclosed |
| EP-0795547-A1 | (Aminoalkyl- and acylaminoalkyl-oxy)benzyloxyquinolines, process for their preparation and use as Bradykinin receptor antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-09-17 | — | — | EP | disclosed |
| US-4401827-A | CARDIOTONIC AND ANTILIPEMIC AGENTS; BLOOD DISORDERS | SIGMA-TAU (IT) | 1983-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051407-A1 | These compounds lack a 1,4-bridging group as found in the ecteinascidins; and, have at the C-1 position a substituent selected from an amino or hydroxy group, optionally protected or derivatized; anticarcinogenic agents | FN1, RCN1, ERCC4 | LMNA 126/4885ALDH1A1 924/4885HDAC3 2693/4885 |
| US-20060019960-A1 | Antitumoral analogs of ET-743 | ETV1, ETV6, ETF1 | LMNA 310/4885ALDH1A1 2332/4885HDAC3 2570/4885 |
| US-11945824-B2 | Heterocyclic compounds as anti-viral agents | VIP, ACE, FURIN | LMNA 2322/4885ALDH1A1 1686/4885HDAC3 246/4885 |
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | VIP, ACE, FURIN | LMNA 2322/4885ALDH1A1 1686/4885HDAC3 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.